Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids

Annals of the Rheumatic Diseases

Volumn 70, Issue 11, 2011, Pages 1887-1894

  Hoes, J N ^a   Van Der Goes, M C ^a   Van Raalte, D H ^b   Van Der Zijl, N J ^b   Den Uyl, D ^b   Lems, W F ^b   Lafeber, F P G J ^a   Jacobs, J W G ^a   Welsing, P M J ^a   Diamant, M ^b   Bijlsma, J W J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PREDNISONE;

ADULT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ADULT; AGED; ANTHROPOMETRY; ARTHRITIS, RHEUMATOID; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED;

EID: 80053564804     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.151464     Document Type: Article

References (32)

1. Peters M J, van Halm VP, Voskuyl AE, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009;61:1571-9.
2. Dessein P H, Joffe BI, Stanwix A, et al. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol 2002;29:462-6. (Pubitemid 34202812)
3. Giorgino F, Almahfouz A, Goodyear LJ, et al. Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo. J Clin Invest 1993;91:2020-30. (Pubitemid 23141474)
4. Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997;99:414-23. (Pubitemid 27414798)
5. Chung C P, Oeser A, Solus JF, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008;58:2105-12. (Pubitemid 351988102)
6. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006;54:2765-75. (Pubitemid 44497755)
7. Shahin D, Eltoraby E, Mesbah A, et al. Insulin resistance in early untreated rheumatoid arthritis patients. Clin Biochem 2010;43:661-5.
8. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32. (Pubitemid 40365093)
9. Simard JF, Mittleman MA. Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older. J Rheumatol 2007;34:469-73. (Pubitemid 46363999)
10. Wild S, Roglic G, Green A, et al. G lobal prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. (Pubitemid 38579764)
11. Buttgereit F, Da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718-22. (Pubitemid 34787710)
12. McMahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev 1988;4:17-30. (Pubitemid 18072099)
13. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoidmediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009;39:81-93.
14. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006;29:2728-9. (Pubitemid 44912208)
15. Gurwitz J H, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97-101. (Pubitemid 24018107)
16. Dessein P H, Joffe BI, Stanwix AE, et al. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol 2004;31:867-74. (Pubitemid 38585808)
17. Wolfe F, Michaud K. Corticosteroids increase the risk of diabetes mellitus in rheumatoid arthritis and contribute to the risk of myocardial infarction and heart failure (abstract). Ann Rheum Dis 2004;63(Suppl 1):495.
18. Svenson K L, Lundqvist G, Wide L, et al. Impaired glucose handling in active rheumatoid arthritis: effects of corticosteroids and antirheumatic treatment. Metab Clin Exp 1987;36:944-8. (Pubitemid 17160511)
19. Hällgren R, Berne C. Glucose intolerance in patients with chronic inflammatory diseases is normalized by glucocorticoids. Acta Med Scand 1983;213:351-5. (Pubitemid 13062556)
20. Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res 2002;4:R12.
21. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95. (Pubitemid 38680001)
22. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003;17:305-22.
23. Prevoo M L, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
24. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60.
25. Kotronen A, Vehkavaara S, Seppälä-Lindroos A, et al. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 2007;293:E1709-15. (Pubitemid 350255123)
26. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21:2191-2. (Pubitemid 28549174)
27. Mari A, Pacini G, Murphy E, et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001;24:539-48. (Pubitemid 32198427)
28. Kosaka K, Hagura R, Kuzuya T, et al. Insulin secretory response of diabetics during the period of improvement of glucose tolerance to normal range. Diabetologia 1974;10:775-82.
29. Han C, Robinson DW, Jr, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72. (Pubitemid 44749774)
30. Smolen J S, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
31. Hoes J N, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560-7. (Pubitemid 350205441)
32. Rho Y H, Chung CP, Solus JF, et al. Adipocytokines, insulin resistance, and coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2010;62:1259-64.